Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Wide Bands | Range Expansion | 2.82% | |
| Upper Bollinger Band Touch | Strength | 2.82% | |
| Crossed Above 20 DMA | Bullish | -2.48% | |
| Crossed Above 200 DMA | Bullish | -2.48% | |
| Crossed Above 50 DMA | Bullish | -2.48% | |
| MACD Bullish Signal Line Cross | Bullish | -2.48% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Rose Above Upper Bollinger Band | about 10 hours ago |
| Up 5% | about 10 hours ago |
| Upper Bollinger Band Resistance | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/01/2024
Vanda Pharmaceuticals Inc. Description
Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Alcohol Oncology Organic Compounds Chemical Compounds Chemotherapy Schizophrenia Central Nervous System Disorders Depression Major Depressive Disorder Nervous System Disorders Depressive Disorder Sleep Disorders Pyridines Treatment Of Major Depressive Disorder Insomnia Nausea Sedatives Treatment Of Schizophrenia Treatment Of Central Nervous System Disorders Pruritus Chemotherapy Induced Nausea Fanapt Iloperidone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.0 |
| 52 Week Low | 3.295 |
| Average Volume | 2,593,142 |
| 200-Day Moving Average | 4.52 |
| 50-Day Moving Average | 4.24 |
| 20-Day Moving Average | 4.37 |
| 10-Day Moving Average | 4.50 |
| Average True Range | 0.37 |
| RSI (14) | 63.77 |
| ADX | 31.3 |
| +DI | 48.03 |
| -DI | 15.80 |
| Chandelier Exit (Long, 3 ATRs) | 4.92 |
| Chandelier Exit (Short, 3 ATRs) | 4.82 |
| Upper Bollinger Bands | 5.29 |
| Lower Bollinger Band | 3.45 |
| Percent B (%b) | 0.9 |
| BandWidth | 42.14 |
| MACD Line | 0.20 |
| MACD Signal Line | 0.12 |
| MACD Histogram | 0.0768 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.67 | ||||
| Resistance 3 (R3) | 5.67 | 5.48 | 5.57 | ||
| Resistance 2 (R2) | 5.48 | 5.34 | 5.48 | 5.54 | |
| Resistance 1 (R1) | 5.30 | 5.25 | 5.39 | 5.30 | 5.51 |
| Pivot Point | 5.11 | 5.11 | 5.16 | 5.11 | 5.11 |
| Support 1 (S1) | 4.93 | 4.97 | 5.02 | 4.93 | 4.71 |
| Support 2 (S2) | 4.74 | 4.88 | 4.74 | 4.68 | |
| Support 3 (S3) | 4.56 | 4.74 | 4.65 | ||
| Support 4 (S4) | 4.56 |
